The lack of sufficient objective response from molecular targeted therapeutics at phase III clinical trials predicated on IDH-WT GBM genomic data [47–51], is in considerable part due to a neglect of intra-tumor heterogeneity [52–57]. The gene discussed is IDH1; the disease is glioblastoma.